To The Moon

$UnitedHealth(UNH)$   UnitedHealth Group (UNH) is currently trading at $250.89, with strong fundamentals and a high dividend yield. Analysts are generally bullish, though short-term capital flows indicate some caution. The stock has a wide target price range, reflecting diverse expectations. Here's a comprehensive overview of UnitedHealth Group (UNH) as of August 10, 2025: Key Metrics Stock Price: $250.89 (USD) Daily Change: +2.54% 52-Week Range : $234.60 - $630.73 (USD) Market Cap: $227.59 billion (USD) Trading Volume: 10.19 million shares Earnings per Share (TTM) : $23.12 P/E Ratio (TTM) : 10.85 Dividend Yield: 8.51% Price-to-Book Ratio : 2.27 ROE: 21.65% ROA: 6.46% Capital Flow & Short Interest 5-Day Capital Flow : Net outflow obse

Two profit sources: 1. Underwriting profit – surplus after paying claims and expenses. 2. Investment income on float – premiums held before claims are paid. • The float is like interest‑free, long‑term capital; as long as underwriting is at least break‑even, it’s effectively free money to invest. • Unlike most businesses where capital must be raised from equity or debt, insurance “loans” you the float. ⸻ 2️⃣ The Compounding Machine • If float grows and underwriting stays profitable, you get more investable funds each year without issuing shares or taking loans. • Investing float in high‑quality businesses compounds wealth far faster than relying only on retained earnings. • Berkshire’s float grew from $39M in 1970 to ~$169B in 2023, all available for investment without interest expense. ⸻

$UnitedHealth(UNH)$ no chance 

$UnitedHealth(UNH)$   ​ Overview: What’s Driving the Decline? Massive drawdown: UNH shares plunged from approximately $600 in mid‑April 2025 to around $241–$260, a decline of ~55–60% . Catalysts: A combination of dramatically rising medical claims, underfunded Medicare Advantage programs (resulting in an 89.4% medical cost ratio)—and regulatory and DOJ scrutiny over billing practices—triggered sharp earnings downgrades and leadership reshuffles . Analyst reviews: Bernstein recently lowered its 12-month target to $337, while UBS maintains a $330 target, and average consensus across 23–24 analysts ranges from $320–$405, signaling potential 30–70% upside if recovery unfolds . Valuation: Current forward P/E sits at ~

$UnitedHealth(UNH)$  I am observing with concern the steep decline in UnitedHealth Group's stock, which has dropped from around $600 in April of this year to its current price near $240. The fact that it has lost 52% year-to-date is alarming, and the speculation that UNH may head to $160 adds to the uncertainty. This significant downturn has caught my attention, especially given the company's previous strength. I have reviewed the chart I attached below, and the monthly candlestick pattern shows an extremely bearish trend. The stock remains well below the EMA200 (green coloured line), a key indicator for me, suggesting that the downward momentum is far from over. This technical analysis reinforces my cautious stance o

$UnitedHealth(UNH)$ UnitedHealth Group (UNH): A 52% Drop Hides a Golden Opportunity UnitedHealth Group (UNH) trades at $241.20, up a modest 0.09% in the last 24 hours, following a staggering 52% year-to-date decline from its April peak near $600. While some predict a further drop to $160, this steep fall is not a death knell but a rare chance to buy a healthcare giant at a discount. With its robust fundamentals and signs of stabilization, UNH is poised for a strong recovery. Here’s why investors should see this as a bullish turning point. The Dip That Defies the Narrative UNH’s 52% drop from $600 to $241.20 has sparked panic, with some eyeing a potential slide to $160. However, this decline reflects broader market volatility and sector-specific pre

$UnitedHealth(UNH)$ In a year where defensive sectors were supposed to shine, UnitedHealth Group (NYSE: UNH) has delivered one of its most shocking performances in recent memory. Once hailed as the gold standard among managed care companies, UnitedHealth has seen its stock collapse by a staggering 52% year-to-date, wiping out hundreds of billions in market capitalization and stunning long-term investors. For a company long regarded as a core holding in any blue-chip dividend or healthcare portfolio, the recent decline raises a simple but consequential question: Has UnitedHealth bottomed—or is the pain just beginning? This is not just a technical correction—it’s a structural repricing that reflects a storm of regulatory risks, Medicare Advantage mar

$UnitedHealth(UNH)$  Will stay volatile fora while. For the daring and patient investors, may be a good time to progressively acquire this stock.  Likely to get significant gains when the issues are over after some time!

$UnitedHealth(UNH)$  Few would have expected UnitedHealth Group (UNH), a long-time Wall Street darling and a symbol of stability, to be among the worst-performing large-cap stocks this year. Yet here we are in 2025, and the stock has collapsed by over 52% year-to-date — a shocking reversal for what was once considered a defensive powerhouse. The big question now? Has UNH hit bottom, or is more pain to come? What's Driving the Meltdown? The selloff didn’t happen in a vacuum. Investors have been spooked by a combination of real business headwinds and shifting macro trends. Among the most pressing concerns: Rising Medical Costs: Post-pandemic, there's been a surge in elective procedures, hospital visits, and utilization

$UnitedHealth(UNH)$  not sure 

$UnitedHealth(UNH)$  300

$UnitedHealth(UNH)$ UnitedHealth (UNH) taking a hit on missed guidance and a soft EPS is a wake-up call for anyone who thought defensive sectors were immune from market risk. The drop to $250—or even close—is significant, putting the stock back near multi-year support levels where long-term holders have stepped in before. With Q2 EPS at $4.08 missing the $4.45 expectation, investors are understandably jittery, even as revenue came in slightly above consensus. So, is UNH a buy at $250? For patient, long-term investors, that price starts to look attractive—especially given UnitedHealth’s dominant position in the healthcare and insurance space. The company still generates massive cash flow, boasts a huge member base, and is embedded in every major U.S

$UnitedHealth(UNH)$  thankssssssss

$UnitedHealth(UNH)$ led the decline of 15 high-quality $Dow Jones(.DJI)$ components with a market capitalization over $100 billion.Do you own any oversold high-quality stocks?📈 Check out TigerAI's analysis.I. $UnitedHealth(UNH)$ declined almost 8 % on Tuesday after releasing earnings.Key facts of $UnitedHealth(UNH)$• Reported 29-Jul-2025 pre-market; stock closed –7.9 %.• Options volume ranked #5 across all US names that day.• YTD 2025 (to 29 Jul) UNH is –48.39 %, the steepest drop among US mega-caps (≥ 100 bn USD).• Tiger Trade “Top Bought” leaderboard: UNH has been the #2 most-bought stock over the last 20-, 10-, 5-, 3- an

$UnitedHealth(UNH)$ UnitedHealth Group (NYSE: UNH) saw its shares drop over 5% following its second-quarter earnings release, bringing the stock down to approximately $268 per share. Year-to-date, the stock has plummeted 46.8%, and over the past 12 months, it’s lost more than half its value. From a 52-week high of $630.73, UNH now trades much closer to its 52-week low of $248.88, set earlier in April. A Mixed Quarter with Troubling Forward Guidance Q2 results presented a mixed picture. Non-GAAP EPS came in at $4.08, missing consensus estimates by $0.37. Revenue was reported at $111.62 billion—up 12.9% year-over-year and in line with expectations. However, what truly rattled investors was the company’s full-year 2025 guidance. Management now expects

I feel relieved that I stuck to my trading plan and cut my losses when $UnitedHealth(UNH)$   broke its support level while I was attempting to buy the dip. Watching the share price tumble further has validated that decision, and I am grateful for avoiding a deeper loss. The news that UnitedHealth tumbled 5% in premarket trading after offering disappointing profit guidance and missing EPS forecasts in Q2 is concerning. The reported Q2 EPS of $4.08 fell short of analysts' expectations of $4.45, which explains the sharp decline. It is disappointing to see such a miss in a company of this stature. On the positive side, the quarterly revenue rose to $111.62 billion, slightly above the consensus forecast of $111.5

$UnitedHealth(UNH)$  Definitely a buy at $250 

$UnitedHealth(UNH)$   ⚠️ UNH Missed Guidance and Plunged: A Buy at $250? $UNH$ stumbled after Q2 earnings — dropping over 5% premarket as EPS came in below expectations. 🧾 EPS: $4.08 vs $4.45 expected 💵 Revenue: $111.62B vs $111.59B forecast 📉 Immediate market reaction: Sharp selloff to $250 — a 52-week low So… is this a value-buying opportunity for a healthcare giant? Or are there deeper structural issues in play? Let’s break it down. ⚖️ --- 💊 Behind the Numbers: Was This Miss Predictable? While UNH beat revenue forecasts, it missed on earnings due to rising costs. 🧬 The key culprit: Medical Cost Ratio (MCR) — which measures how much UNH pays out in care vs what it collects in premiums — ticked above expectation

$UnitedHealth(UNH)$   UnitedHealth Group (UNH) is currently trading at $250.89, with strong fundamentals and a high dividend yield. Analysts are generally bullish, though short-term capital flows indicate some caution. The stock has a wide target price range, reflecting diverse expectations. Here's a comprehensive overview of UnitedHealth Group (UNH) as of August 10, 2025: Key Metrics Stock Price: $250.89 (USD) Daily Change: +2.54% 52-Week Range : $234.60 - $630.73 (USD) Market Cap: $227.59 billion (USD) Trading Volume: 10.19 million shares Earnings per Share (TTM) : $23.12 P/E Ratio (TTM) : 10.85 Dividend Yield: 8.51% Price-to-Book Ratio : 2.27 ROE: 21.65% ROA: 6.46% Capital Flow & Short Interest 5-Day Capital Flow : Net outflow obse

$UnitedHealth(UNH)$ UnitedHealth Group (UNH): A 52% Drop Hides a Golden Opportunity UnitedHealth Group (UNH) trades at $241.20, up a modest 0.09% in the last 24 hours, following a staggering 52% year-to-date decline from its April peak near $600. While some predict a further drop to $160, this steep fall is not a death knell but a rare chance to buy a healthcare giant at a discount. With its robust fundamentals and signs of stabilization, UNH is poised for a strong recovery. Here’s why investors should see this as a bullish turning point. The Dip That Defies the Narrative UNH’s 52% drop from $600 to $241.20 has sparked panic, with some eyeing a potential slide to $160. However, this decline reflects broader market volatility and sector-specific pre

$UnitedHealth(UNH)$ In a year where defensive sectors were supposed to shine, UnitedHealth Group (NYSE: UNH) has delivered one of its most shocking performances in recent memory. Once hailed as the gold standard among managed care companies, UnitedHealth has seen its stock collapse by a staggering 52% year-to-date, wiping out hundreds of billions in market capitalization and stunning long-term investors. For a company long regarded as a core holding in any blue-chip dividend or healthcare portfolio, the recent decline raises a simple but consequential question: Has UnitedHealth bottomed—or is the pain just beginning? This is not just a technical correction—it’s a structural repricing that reflects a storm of regulatory risks, Medicare Advantage mar

$UnitedHealth(UNH)$  Few would have expected UnitedHealth Group (UNH), a long-time Wall Street darling and a symbol of stability, to be among the worst-performing large-cap stocks this year. Yet here we are in 2025, and the stock has collapsed by over 52% year-to-date — a shocking reversal for what was once considered a defensive powerhouse. The big question now? Has UNH hit bottom, or is more pain to come? What's Driving the Meltdown? The selloff didn’t happen in a vacuum. Investors have been spooked by a combination of real business headwinds and shifting macro trends. Among the most pressing concerns: Rising Medical Costs: Post-pandemic, there's been a surge in elective procedures, hospital visits, and utilization

$UnitedHealth(UNH)$   ​ Overview: What’s Driving the Decline? Massive drawdown: UNH shares plunged from approximately $600 in mid‑April 2025 to around $241–$260, a decline of ~55–60% . Catalysts: A combination of dramatically rising medical claims, underfunded Medicare Advantage programs (resulting in an 89.4% medical cost ratio)—and regulatory and DOJ scrutiny over billing practices—triggered sharp earnings downgrades and leadership reshuffles . Analyst reviews: Bernstein recently lowered its 12-month target to $337, while UBS maintains a $330 target, and average consensus across 23–24 analysts ranges from $320–$405, signaling potential 30–70% upside if recovery unfolds . Valuation: Current forward P/E sits at ~

$UnitedHealth(UNH)$ led the decline of 15 high-quality $Dow Jones(.DJI)$ components with a market capitalization over $100 billion.Do you own any oversold high-quality stocks?📈 Check out TigerAI's analysis.I. $UnitedHealth(UNH)$ declined almost 8 % on Tuesday after releasing earnings.Key facts of $UnitedHealth(UNH)$• Reported 29-Jul-2025 pre-market; stock closed –7.9 %.• Options volume ranked #5 across all US names that day.• YTD 2025 (to 29 Jul) UNH is –48.39 %, the steepest drop among US mega-caps (≥ 100 bn USD).• Tiger Trade “Top Bought” leaderboard: UNH has been the #2 most-bought stock over the last 20-, 10-, 5-, 3- an

$UnitedHealth(UNH)$ UnitedHealth Group (NYSE: UNH) saw its shares drop over 5% following its second-quarter earnings release, bringing the stock down to approximately $268 per share. Year-to-date, the stock has plummeted 46.8%, and over the past 12 months, it’s lost more than half its value. From a 52-week high of $630.73, UNH now trades much closer to its 52-week low of $248.88, set earlier in April. A Mixed Quarter with Troubling Forward Guidance Q2 results presented a mixed picture. Non-GAAP EPS came in at $4.08, missing consensus estimates by $0.37. Revenue was reported at $111.62 billion—up 12.9% year-over-year and in line with expectations. However, what truly rattled investors was the company’s full-year 2025 guidance. Management now expects

$UnitedHealth(UNH)$  I am observing with concern the steep decline in UnitedHealth Group's stock, which has dropped from around $600 in April of this year to its current price near $240. The fact that it has lost 52% year-to-date is alarming, and the speculation that UNH may head to $160 adds to the uncertainty. This significant downturn has caught my attention, especially given the company's previous strength. I have reviewed the chart I attached below, and the monthly candlestick pattern shows an extremely bearish trend. The stock remains well below the EMA200 (green coloured line), a key indicator for me, suggesting that the downward momentum is far from over. This technical analysis reinforces my cautious stance o

UnitedHealth Group ( $UnitedHealth(UNH)$ ) faced a rough start to the week, tumbling 5% in premarket trading after its Q2 2025 earnings report on July 29, 2025, missed earnings per share (EPS) expectations and offered a disappointing profit outlook. The health insurance giant reported a Q2 EPS of $4.08, falling short of the consensus forecast of $4.45, while revenue of $111.62 billion slightly exceeded the $111.59 billion expected. With the stock now hovering around $266.10 after the drop, investors are eyeing a potential dip to $250—a level not seen since earlier this year. Is this a golden opportunity to buy a healthcare leader at a discount, or a risky bet amid ongoing challenges? This report dives into UNH’s earnings, the reasons behind the mis

$Novo-Nordisk A/S(NVO)$ was scheduled to report Q2 earnings on Aug. 6, but chose to issue an early earnings warning.There has also been a change of CEO, with Maziar Mike Doustda replacing Lars Fruergaard Jørgensen on August 7th.Earnings warning and market reactionSales & Profit Adjustments: Full year 2025 sales growth estimate is lowered to 8%-14% (CER ) from 13%-21% (CER) and operating profit growth is lowered to 10%-16% (CER) from 16%-24%, which is significantly lower than analysts' expectations of 16.6%. In Danish krone terms, sales and profit growth fell by a further 4% and 7% respectively, mainly due to the depreciation of the US dollar.The core driver of the downgrade stems from Wegovy, with lower-than-expected penetration in the out-of-p

$UnitedHealth(UNH)$   ⚠️ UNH Missed Guidance and Plunged: A Buy at $250? $UNH$ stumbled after Q2 earnings — dropping over 5% premarket as EPS came in below expectations. 🧾 EPS: $4.08 vs $4.45 expected 💵 Revenue: $111.62B vs $111.59B forecast 📉 Immediate market reaction: Sharp selloff to $250 — a 52-week low So… is this a value-buying opportunity for a healthcare giant? Or are there deeper structural issues in play? Let’s break it down. ⚖️ --- 💊 Behind the Numbers: Was This Miss Predictable? While UNH beat revenue forecasts, it missed on earnings due to rising costs. 🧬 The key culprit: Medical Cost Ratio (MCR) — which measures how much UNH pays out in care vs what it collects in premiums — ticked above expectation

I feel relieved that I stuck to my trading plan and cut my losses when $UnitedHealth(UNH)$   broke its support level while I was attempting to buy the dip. Watching the share price tumble further has validated that decision, and I am grateful for avoiding a deeper loss. The news that UnitedHealth tumbled 5% in premarket trading after offering disappointing profit guidance and missing EPS forecasts in Q2 is concerning. The reported Q2 EPS of $4.08 fell short of analysts' expectations of $4.45, which explains the sharp decline. It is disappointing to see such a miss in a company of this stature. On the positive side, the quarterly revenue rose to $111.62 billion, slightly above the consensus forecast of $111.5

Two profit sources: 1. Underwriting profit – surplus after paying claims and expenses. 2. Investment income on float – premiums held before claims are paid. • The float is like interest‑free, long‑term capital; as long as underwriting is at least break‑even, it’s effectively free money to invest. • Unlike most businesses where capital must be raised from equity or debt, insurance “loans” you the float. ⸻ 2️⃣ The Compounding Machine • If float grows and underwriting stays profitable, you get more investable funds each year without issuing shares or taking loans. • Investing float in high‑quality businesses compounds wealth far faster than relying only on retained earnings. • Berkshire’s float grew from $39M in 1970 to ~$169B in 2023, all available for investment without interest expense. ⸻

$UnitedHealth(UNH)$ UnitedHealth (UNH) taking a hit on missed guidance and a soft EPS is a wake-up call for anyone who thought defensive sectors were immune from market risk. The drop to $250—or even close—is significant, putting the stock back near multi-year support levels where long-term holders have stepped in before. With Q2 EPS at $4.08 missing the $4.45 expectation, investors are understandably jittery, even as revenue came in slightly above consensus. So, is UNH a buy at $250? For patient, long-term investors, that price starts to look attractive—especially given UnitedHealth’s dominant position in the healthcare and insurance space. The company still generates massive cash flow, boasts a huge member base, and is embedded in every major U.S

For $UnitedHealth(UNH)$  , I can only say that I am fortunate. Fortunate to not be overly blinded by other savvy investors who advocate that UNH is highly undervalued and hence a good buy, and sell in time. I do believe that it is undervalued. But with all the ngativity and uncertainty on its financials, it is likely that the share price will plummet further and become even more undervalued. Will watch and observe when it is a good time to buy in again

$UnitedHealth(UNH)$  Will stay volatile fora while. For the daring and patient investors, may be a good time to progressively acquire this stock.  Likely to get significant gains when the issues are over after some time!

✨️WHAT IS UNITED HEALTH STOCK✨️ Headquartered in Minnesota, UnitedHealth is one of the most influential players in the U.S. healthcare system. The company operates a suite of offerings including health maintenance organizations, preferred provider organizations, point-of-service plans, and managed fee-for-service programs. As of now, UnitedHealth commands a market capitalization of $280 billion. However, its stock performance has been anything but steady. In the past three months alone, UNH has slipped 40%. From its 52-week high of $630.73, the drop extends to 50%, a fall that has rattled long-time shareholders. Yet, beneath this decline lies a potential value proposition. Currently, UNH trades at 13.7 times forward adjusted earnings and just 0.69 times sales, Both of these valuation metri

$UnitedHealth(UNH)$ no chance 

$UnitedHealth(UNH)$ In a year marked by tech exuberance, speculative growth rebounds, and lingering fears of a macroeconomic slowdown, one of the market’s most consistent performers isn’t a high-flying AI startup or a mega-cap cloud darling—it’s UnitedHealth Group (NYSE: UNH). As one of the largest and most influential players in the healthcare space, UnitedHealth has quietly become a pillar of market stability and predictable growth. While investors chase returns in volatile sectors, UNH is demonstrating that defensive doesn’t mean stagnant. In fact, the company’s strong earnings, durable cash flows, and expanding footprint in both insurance and health services may signal that “defense is the new offense” for long-term portfolios. Its steady rise